

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)



(10) International Publication Number
WO 2022/090211 A1

(51) International Patent Classification:

C07K 14/34 (2006.01) *C12N 1/36* (2006.01)
A61K 38/00 (2006.01) *C12N 15/70* (2006.01)
A61P 35/00 (2006.01) *C12N 15/74* (2006.01)
C12N 1/20 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/079654

(22) International Filing Date:

26 October 2021 (26.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20204007.7 27 October 2020 (27.10.2020) EP

(71) Applicant: **T3 PHARMACEUTICALS AG** [CH/CH]; c/o Biozentrum, Universität Basel, Klingelbergstrasse 50/70, 4056 Basel (CH).

(72) Inventors: **AMSTUTZ, Marlise**; Wittlingerstrasse 140, 4058 Basel (CH). **ITTIG, Simon**; Zehntenfreistrasse 32, 4103 Bottmingen (CH). **KASPER, Christoph**; Fustliweg 19, 4600 Olten (CH). **DICK, Mathias, S.**; Rämelsstrasse 5, 4055 Basel (CH). **SAUPE, Falk**; Schorenweg 38, 4058 Basel (CH).

(74) Agent: **SCHÖLLHORN, Andreas** et al.; LATSCHA SCHÖLLHORN PARTNER AG, Grellingerstrasse 60, 4052 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: BACTERIA BASED PROTEIN DELIVERY

(57) Abstract: The present invention relates to recombinant Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

WO 2022/090211 A1